summary: In this multicentre randomised controlled trial the authors studied the effect of intravenous immunoglobulin in people with relapsing remitting MS. Unfortunately it was not of benefit.

authors: Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K; PRIVIG Study Group; UBC MS/MRI Research Group.

source: Neurology. 2008 Jul 22;71(4):265-71.

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: